Table 2.
Characteristics of the study patients.
| Characteristic | N (%) |
|---|---|
| Female | 144 (47.4%) |
| Male | 160 (52.6%) |
| Total | 304 (100%) |
| % mixed Caucasian–aboriginal ethnicity | 9.80% |
| Age ± SD [range] (years) | 65.01 ± 13.99 [22–95] |
| Body mass index (BMI) (kg/m2) ± SD (median) | 29.2 ± 5.7 (28.4) |
| INR range | 2.0–3.0 |
| Acenocoumarol | 100% |
| Weekly therapeutic dose of acenocoumarol (mg/week) ± SD | 14.6 ± 2.2 |
| Acenocoumarol dosage, mg/week; range (median) | 3.5–46 (13) |
| Time to reach therapeutic range (days); average ± SD | 308 ± 343 |
| Time to reach therapeutic range (days); range (median) | 3–353 (206) |
| Primary diagnosis | N (%) |
| Rhythm disorder | 156 (51.3%) |
| Venous thrombosis with/without pulmonary thromboembolism | 64 (21.1%) |
| Occlusive arterial disease | 24 (7.9%) |
| Stroke | 17 (5.6%) |
| Others | 43 (14.1%) |
| Total | 304 (100%) |
| Secondary diagnosis | N (%) |
| Arterial hypertension | 64 (25.6%) |
| Diabetes mellitus | 27 (10.8%) |
| Cardiomyopathy | 26 (10.4%) |
| Other | 88 (42.9%) |
| Total | 205 (100%) |
SD, standard deviation.